Clinical Trial Update: A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating TQA3605 tablets for treatment-naive chronic hepatitis B was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• TQA3605

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Chronic Hepatitis B | Phase 2 | Status: WITHDRAWN